UK-VNCCLL-210585. Date of Preparation: January 2022.
Video library
Haematology experts provide their opinions on key areas in the treatment of CLL patients
Clinical data for Venclyxto®▼(venetoclax) in CLL
Expert Conversations in CLL clinical data and patient communication
CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.
References
- VENCLYXTO Summary of Product Characteristics.
- Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
- Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-VNCCLL-210546. Date of preparation: November 2021.